A randomized placebo‐controlled lovastatin trial for neurobehavioral function in neurofibromatosis I

OBJECTIVE: Lovastatin has been shown to reverse learning deficits in a mouse model of Neurofibromatosis Type 1 (NF1), a common monogenic disorder caused by a mutation in the Ras‐MAPK pathway and associated with learning disabilities. We conducted a randomized double‐blind placebo‐controlled trial to...

Descripción completa

Detalles Bibliográficos
Autores principales: Bearden, Carrie E., Hellemann, Gerhard S., Rosser, Tena, Montojo, Caroline, Jonas, Rachel, Enrique, Nicole, Pacheco, Laura, Hussain, Shaun A., Wu, Joyce Y., Ho, Jennifer S., McGough, James J., Sugar, Catherine A., Silva, Alcino J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4818747/
https://www.ncbi.nlm.nih.gov/pubmed/27081657
http://dx.doi.org/10.1002/acn3.288

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4818747/
https://www.ncbi.nlm.nih.gov/pubmed/27081657
http://dx.doi.org/10.1002/acn3.288

Ejemplares similares